Grufity logoGrufity logo

TWST

25.44USD-0.09(-0.35%)Market Closed

Twist Bioscience Corp

Market Summary

USD25.44-0.09Market Closed
-0.35%

TWST Stock Price

RSI Chart

Valuation

Market Cap

1.9B

Price/Earnings

-9.05

Price/Sales

10.21

Price/Cashflow

-11.91

MarketCap/EBT

-8.62

Price/Sales

Profitability

Operating Margin

40.15%

EBT Margin

-118.53%

Return on Equity

-25.34%

Return on Assets

-21.23%

Fundamentals

Revenue

Revenue (TTM)

184.2M

Revenue Y/Y

60.24%

Revenue Q/Q

16.59%

Earnings

Earnings (TTM)

-208.0M

Earnings Y/Y

-51.15%

Earnings Q/Q

0.25%

Price Action

52 Week Range

23.9099.74
(Low)(High)

Last 7 days

2.5%

Last 30 days

-23.7%

Last 90 days

-41.0%

Trailing 12 Months

-73.4%

Financial Health

Current Ratio

6.73

Debt/Equity

0.01

Debt/Cashflow

-32.16

Investor Care

Shares Dilution (1Y)

14.35%

Diluted EPS (TTM)

-3.95

Peers (Alternatives to Twist Bioscience)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
146.5B
26.3B
7.14% 43.50%
22.27
5.55
2.18% 21.86%
99.4B
27.1B
21.80% 28.96%
24.02
3.61
-1.26% -54.91%
59.1B
23.0B
24.23% -35.48%
4.2
2.57
227.55% 302.16%
41.3B
10.4B
8.82% 22.00%
14.4
3.98
-6.64% 85.32%
11.1B
1.4B
7.16% 39.03%
905.99
8.52
29.86% -86.92%
MID-CAP
3.7B
112.4M
7.23% -37.09%
-12.87
32.5
-41.50% -607.58%
3.4B
-
-6.88% -45.94%
-14.65
59.51
215916.67% 21.41%
2.1B
68.3M
-4.89% -63.56%
-8.33
30.98
42.18% -19.70%
2.0B
432.8M
-5.28% -44.88%
29.99
4.9
1042.97% 128.67%
SMALL-CAP
1.8B
1.8B
-27.49% -91.73%
-1.22
1.39
53.41% -22.97%
1.6B
69.7M
-21.14% -78.94%
-3.15
20.84
745.14% -7.72%
891.0M
3.2M
12.62% -35.50%
-6.7
275.59
11.14% -46.59%
692.0M
114.2M
-18.16% -60.18%
-4.02
6.06
-17.11% -27.41%
458.1M
-
-23.83% -90.20%
-13.56
44.06
522.71% -129.91%
218.9M
-
-24.71% -82.02%
-2.36
609.63
-71.03% -64.56%

Financials for Twist Bioscience

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Revenue12.9%184163146132127
  S&GA Expenses10.8%197178158136125
  R&D Expenses18.3%11093786961
Earnings Before Taxes-9.1%-218.35-200.10-177.14-154.03-137.18
Net Income-10.9%-207.99-187.51-164.76-152.10-135.17
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Assets-4.1%9801,022786702725
  Current Assets-6.1%624664385546577
    Cash Equivalents-7.7%376408192466475
  Inventory-3.5%4345403221
  Net PPE38.3%12792654438
  Goodwill0.2%8686842223
Liabilities0.4%159158160121115
  Current Liabilities9.5%9385806355
    LT Debt, CurrentNaN%--22-
Shareholder's Equity-4.9%821863626581610
  Retained Earnings-8.4%-777.30-716.78-656.10-610.55-569.31
  Additional Paid-In Capital1.2%1,5991,5811,2821,1911,179
Accumulated Depreciation-35----
Shares Outstanding0.2%5656514949
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Cashflow From Operations-4.1%-157.92-151.76-133.96-112.24-102.64
  Share Based Compensation18.1%7059483733
Cashflow From Investing-90.1%-211.80-111.39-24.5115638
Cashflow From Financing-0.2%2712711329333

Risks

What is the probability of a big loss on TWST?

97.2%


Probability that Twist Bioscience stock will be more than 20% underwater in next one year

96.7%


Probability that Twist Bioscience stock will be more than 30% underwater in next one year.

60.9%


Probability that Twist Bioscience stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does TWST drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Twist Bioscience was unfortunately bought at previous high price.

Returns

Cumulative Returns on TWST

3.1%


3-Year Cumulative Returns

Which funds bought or sold TWST recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-23
Eagle Bay Advisors LLC
UNCHANGED
-
392
2,000
-%
2022-11-22
B. Riley Wealth Advisors, Inc.
REDUCED
-12.07
-32,000
250,000
0.01%
2022-11-22
Capital Impact Advisors, LLC
-
-
-144,000
487,000
0.48%
2022-11-21
FourThought Financial, LLC
-
-
-
14,000
-%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
-
-
-87,000
2,402,000
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-27,000
-
-%
2022-11-15
Balyasny Asset Management LLC
REDUCED
-24.78
-2,636,000
8,269,000
0.03%
2022-11-15
ADVISORY RESEARCH INC
SOLD OFF
-100
-473,000
-
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
UNCHANGED
-
-
8,000
-%
2022-11-15
STATE STREET CORP
REDUCED
-24.97
-32,509,000
100,905,000
0.01%

1–10 of 45

Latest Funds Activity

Are funds buying TWST calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own TWST

Twist Bioscience News

Benzinga

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Twist Bioscience Cor.12 hours ago

TWST Fair Value

Recent SEC filings of Twist Bioscience

View All Filings
Date Filed Form Type Document
Nov 23, 2022
4
Insider Trading
Nov 23, 2022
4
Insider Trading
Nov 22, 2022
4
Insider Trading
Nov 22, 2022
4
Insider Trading
Nov 22, 2022
4
Insider Trading
Nov 22, 2022
4
Insider Trading
Nov 22, 2022
4
Insider Trading
Nov 21, 2022
4
Insider Trading
Nov 18, 2022
8-K
Current Report
Nov 18, 2022
8-K
Current Report

Latest Insider Trading transactions for TWST

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-21
Banyai William
SOLD
-31,747.5
24.9
-1,275
See Remarks
2022-11-21
BARTHELEMY NICOLAS
ACQUIRED
211,883
23.33
9,082
-
2022-11-18
Finn Patrick John
SOLD FOR TAXES
-25,479.9
24.81
-1,027
President and COO
2022-11-18
Leproust Emily M.
SOLD FOR TAXES
-68,525.2
24.81
-2,762
Chief Executive Officer
2022-11-18
THORBURN JAMES M
SOLD FOR TAXES
-25,479.9
24.81
-1,027
Chief Financial Officer
2022-11-18
Green Paula
SOLD FOR TAXES
-6,450.6
24.81
-260
SVP of Human Resources
2022-11-18
Banyai William
SOLD FOR TAXES
-16,746.8
24.81
-675
See Remarks
2022-11-17
Yankton Kevin Bruce
SOLD FOR TAXES
-1,524
25.4
-60
Chief Accounting Officer
2022-10-25
Banyai William
SOLD
-11,199.5
29.55
-379
See Remarks
2022-10-24
THORBURN JAMES M
SOLD FOR TAXES
-7,997
29.08
-275
Chief Financial Officer

1–10 of 50

Emily M. Leproust
650
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.

TWST Income Statement

2022-06-30
Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Statement of Comprehensive Income [Abstract]    
Revenues$ 56,113$ 35,018$ 146,259$ 94,382
Operating expenses:    
Cost of revenues30,97420,93387,74458,123
Research and development36,84019,83890,70149,629
Selling, general and administrative53,69334,478158,79097,658
Change in fair value of contingent considerations and holdbacks(4,231)1,887(13,071)1,887
Total operating expenses117,27677,136324,164207,297
Loss from operations(61,163)(42,118)(177,905)(112,915)
Interest income722861,134377
Interest expense0(70)(54)(284)
Other income (expense), net(225)(312)(626)(305)
Loss before income taxes(60,666)(42,414)(177,451)(113,127)
Benefit from income taxes1492,37710,7032,271
Net loss attributable to common stockholders(60,517)(40,037)(166,748)(110,856)
Other comprehensive loss:    
Change in unrealized loss on investments(404)(12)(1,794)(10)
Foreign currency translation adjustment(498)250(129)351
Comprehensive loss$ (61,419)$ (39,799)$ (168,671)$ (110,515)
Net loss per share attributable to common stockholders—basic (in usd per share)$ (1.08)$ (0.82)$ (3.15)$ (2.32)
Net loss per share attributable to common stockholders—diluted (in usd per share)$ (1.08)$ (0.82)$ (3.15)$ (2.32)
Weighted average shares used in computing net loss per share attributable to common stockholders—basic (in shares)56,28748,96353,00547,881
Weighted average shares used in computing net loss per share attributable to common stockholders—diluted (in shares)56,28748,96353,00547,881

TWST Balance Sheet

2022-06-30
Condensed Consolidated Balance Sheets (unaudited) - USD ($)
$ in Thousands
Jun. 30, 2022
Sep. 30, 2021
Current assets:  
Cash and cash equivalents$ 376,249$ 465,829
Short-term investments151,34212,034
Accounts receivable, net41,19528,549
Inventories43,02231,800
Prepaid expenses and other current assets12,3098,283
Total current assets624,117546,495
Property and equipment, net127,01144,122
Operating lease right-of-use assets76,16561,580
Goodwill85,81122,434
Intangible assets, net61,11518,262
Restricted cash, non-current1,5721,530
Other non-current assets3,8727,674
Total assets[1]979,663702,097
Current liabilities:  
Accounts payable21,01414,900
Accrued expenses9,4996,437
Accrued compensation27,69822,327
Current portion of operating lease liability14,3528,213
Current portion of long-term debt01,552
Other current liabilities20,1239,623
Total current liabilities92,68663,052
Operating lease liability, net of current portion64,24453,156
Other non-current liabilities2,0565,068
Total liabilities[1]158,986121,276
Commitments and contingencies
Stockholders’ equity  
Common stock, $0.00001 par value—100,000 and 100,000 shares authorized at June 30, 2022 and September 30, 2021, respectively; 56,344 and 49,499 shares issued and outstanding at June 30, 2022 and September 30, 2021, respectively00
Additional paid-in capital1,599,3551,190,828
Accumulated other comprehensive income(1,377)546
Accumulated deficit(777,301)(610,553)
Total stockholders’ equity820,677580,821
Total liabilities and stockholders’ equity$ 979,663$ 702,097
[1]The Company’s consolidated assets as of June 30, 2022 include $7,429 in assets of the variable interest entity, or “VIE”, that can only be used to settle obligations of the VIE. Cash as of June 30, 2022 was $6,989; prepaid expenses as of June 30, 2022 were $433 and deposits as of June 30, 2022 were $7. The Company’s consolidated liabilities as of June 30, 2022 were $10,494 in liabilities of the VIE who creditors have no recourse to the Company. These liabilities include accounts payable of $6,412 as of June 30, 2022; accrued expenses and other current liabilities of $2,082 as of June 30, 2022; and other non-current liabilities of $2,000 as of June 30, 2022.